Short-term and long-term remission after endoscopic transnasal adenomectomy in patients with acromegaly

BACKGROUND. Neurosurgery is the most effective treatment for acromegaly. As most of the patients present with macroadenomas, surgical treatment is not always successful, even with the expert level of a neurosurgeon. Assessment of the postoperative remission rates in acromegaly preoperative predictors of treatment efficacy is an urgent task of modern research. AIM: To assess the short-term and long-term remission of acromegaly after endoscopic transnasal adenomectomy in a tertiary medical center and assess preoperative predictors of the treatment effectiveness.
MATERIALS AND METHODS: A single-center, prospective, uncontrolled study was conducted. We included patients with active acromegaly who did not receive medical therapy with somatostatin analogues and were referred for endoscopic transsphenoidal adenomectomy. Plasma miRNA expression was assessed by quantitative reverse transcription PCR. Postoperative samples of adenomas were sent for study, with the determination of the immunohistochemical staining for somatostatin receptors 2 and 5 subtypes and morphology was performed on postoperative adenoma samples.
RESULTS: The study included 44 patients: 32.8% men, median age 47.0 [34.0; 55.0], IGF-1 744.75 ng/ml [548.83;889.85], growth hormone 9.5 ng/ml [4.94; 17.07]. Tumor volume 832 mm3 [419.25; 2532.38]. Early postoperative remission was achieved in 35 patients (79.5%). Patients who achieved short-term remission had higher IGF-1 and basal growth hormone levels. Median follow-up was 19.0 months [12.5;29.0]. Long-term remission was achieved in 61.4% (27 patients), no remission in 9 (20.5%), recurrency in 2 patients (4.5%), 6 patients were to follow-up (13.6%). In patients with long-term remission, we observed lower growth hormone and IGF-1 levels. No differences in miRNA expression was observesd. The predictive value of basal GH before surgery for long-term remission was assessed: area under the curve 0.811 (95% CI: 0.649; 0.973). A cut-off value of 15.55 ng/mL corresponded to a sensitivity of 70.0% (34.8%; 93.3%), a specificity of 85.7% (67.3%; 96.0%), an accuracy of 81.6% (65 .7%; 92.3%), PPV 63.6% (39.3%; 82.5%), NPV 88.9% (75.4%; 95.4%).
CONCLUSION: Rates of short-term and long-term remission after endoscopic transsphenoidal adenomectomy in our cohort is 79,5% и 61,4%, respectively, and is comparable with literature data for expert pituitary centers. Preoperative GH shows potential value in predicting the long-term remission of acromegaly, but further studies in a larger sample are needed to obtain more accurate cut-off values.

1. Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Prim. 2019;5(1):20. doi: https://doi.org/10.1038/s41572-019-0071-6

2. Pronin EV, Pronin VS. Contribution of somatostatin analogues to the implementation of a patient-oriented approach to the treatment of acromegaly. Pharmateca. 2020;(12):99-106. (In Russ.). doi: https://doi.org/10.18565/pharmateca.2020.12.99-106

3. Przhiyalkovskaya EG, Osmanova PO, Mamedova EO, et al. Predictive biomarkers in the treatment of acromegaly: a review of the literature. Ann Russ Acad Med Sci. 2020;74(6):430-440. doi: https://doi.org/10.15690/vramn1181

4. Golounina OO, Dzeranova LK, Pigarova EA, Belaya ZE. Resistance to drug treatment of acromegaly and ways to overcome it. Obe Metab. 2021;18(2):150-162. doi: https://doi.org/10.14341/omet12710

5. Chen C-J, Ironside N, Pomeraniec IJ, et al. Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications. Acta Neurochir (Wien). 2017;159(11):2193-2207. doi: https://doi.org/10.1007/s00701-017-3318-6

6. Di Chiro G, Nelson KB. The volume of the sella turcica. Am J Roentgenol Radium Ther Nucl Med. 1962;(87):989-1008. [cited 20.12.2022]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/13885978

7. Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. 2017;28(3):228-243. doi: https://doi.org/10.1007/s12022-017-9498-z

8. Lutsenko AS, Belaya ZE, Przhiyalkovskaya EG, et al. Expression of plasma microRNA in patients with acromegaly. Problems of Endocrinology. 2019;65(5):311-318. doi: https://doi.org/10.14341/probl10263

9. Lutsenko A, Belaya Z, Nikitin A, et al. Circulating Plasma MicroRNA in Patients With Active Acromegaly. J Clin Endocrinol Metab. 2022;107(2):500-511. doi: https://doi.org/10.1210/clinem/dgab695

10. Petrossians P, Daly AF, Natchev E, et al. Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. Endocr Relat Cancer. 2017;24(10):505-518. doi: https://doi.org/10.1530/ERC-17-0253

11. Coopmans EC, Postma MR, Wolters TLC, et al. Predictors for remission after transsphenoidal surgery in acromegaly: A Dutch multicenter study. J Clin Endocrinol Metab. 2021;106(6):1783-1792. doi: https://doi.org/10.1210/clinem/dgab069

12. Jane JA, Starke RM, Elzoghby MA, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab. 2011;96(9):2732-2740. doi: https://doi.org/10.1210/jc.2011-0554

13. Yao S, Chen W-L, Tavakol S, et al. Predictors of postoperative biochemical remission in acromegaly. J Neurooncol. 2021;151(2):313-324. doi: https://doi.org/10.1007/s11060-020-03669-4

14. Kasuki L, Marques NV, Nuez MJB La, et al. Acromegalic patients lost to follow-up: a pilot study. Pituitary. 2013;16(2):245-250. doi: https://doi.org/10.1007/s11102-012-0412-x